Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Novartis posts eye drug data amid play for Eylea's turf

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 11:42pm CET
Swiss drugmaker Novartis' logo is seen in Stein

ZURICH (Reuters) - Novartis's (>> Novartis) bid to move in on Bayer's (>> Bayer) and Regeneron's (>> Regeneron Pharmaceuticals) eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.

ZURICH (Reuters) - Novartis's (>> Novartis) bid to move in on Bayer's (>> Bayer) and Regeneron's (>> Regeneron Pharmaceuticals) eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.

Active disease was observed in 23.5 percent of RTH258 patients versus 33.5 percent of Eylea patients at 16 weeks, Novartis said, of its investigational treatment for wet age-related macular degeneration (AMD), where abnormal, leaky blood vessels can cause blindness.

A second, similar study found active disease in 21.9 percent of RTH258 patients versus 31.4 percent of those on Eylea for the condition affecting 20-25 million people worldwide.

Novartis in June touted initial data showing its drug may require fewer injections directly into the eye than Eylea, while matching it on vision and safety measures.

The Basel-based drugmaker hopes this latest analysis lends RTH258 additional muscle when matched head-to-head with Eylea as well as Lucentis, which Roche (>> Roche Holding Ltd.) sells in the United States.

"When you take all of that together ... we believe we have a very compelling proposition," Vas Narasimhan, Novartis's chief drug developer who will become CEO in 2018, said on a conference call.

Novartis, which released the data at the American Academy of Opthalmology conference in New Orleans, predicts RTH258 annual sales will top $1 billion and aims to file for U.S. approval in late 2018.

Making it a success is by no means clear sailing.

For one, Novartis owns Lucentis rights in Europe where it has contractual obligations to continue marketing that drug. Analysts say cannibalization from RTH258 will be a challenge.

Competition abounds, too: Eylea, with $5 billion in annual sales, has made inroads against the $3.2 billion-per-year Lucentis, whose 2020 U.S. patent expiration will expose it to cheaper copies.

Moreover, Roche's cancer drug Avastin is effective in off-label AMD use and has won favour because it costs a fraction of Lucentis and Eylea. In Britain, Novartis and Bayer are fighting doctor groups aiming to switch to Avastin.

NEEDLE IN THE EYE

Other would-be rivals are racing to market, too.

Allergan (>> Allergan plc), whose investigational Abicipar is in Phase III trials, is also trumpeting prospects of reduced injections compared to Lucentis. Gene therapies may also be on the distant horizon.

Still, Novartis's Narasimhan remains optimistic for RTH258's reception when it hits the market, likely in 2019.

"When you actually see an image of a patient having a needle inserted into their eye, this is something patients definitely want to avoid," he said.

"Retinal surgeons have busy offices and want to do more complex retinal surgery. Today, they have offices filled with patients waiting for injections."

(Reporting by John Miller; Editing by Adrian Croft)

By John Miller

Valeurs citées dans l'article
ChangeLast1st jan.
BAYER 0.01% 98.44 Delayed Quote.-5.36%
MOLECULAR PARTNERS AG 1.69% 27 Delayed Quote.0.95%
NOVARTIS -0.27% 79.98 Delayed Quote.-2.67%
REGENERON PHARMACEUTICALS -0.07% 317.0466 Delayed Quote.-14.08%
ROCHE HOLDING LTD. -0.09% 223.3 Delayed Quote.-9.33%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
02:01pALLERGAN : FDA Acceptance of Medicines360's Filing for supplemental New Drug App..
PR
02/20ALLERGAN : Presents Data at the 2018 American Academy of Dermatology Annual Meet..
AQ
02/17ALLERGAN : Presents Data at the 2018 American Academy of Dermatology (AAD) Annua..
PU
02/16ALLERGAN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
02/15ALLERGAN : Trademark Application for "REJUVACROSS" Filed by Allergan
AQ
02/15ALLERGAN : An Application for the Trademark "REJUVECROSS" Has Been Filed by Alle..
AQ
02/15ALLERGAN : Matthew M. Walsh Appointed Executive Vice President and Chief Financi..
AQ
02/14ALLERGAN : s Forest Labs pays 726m in dividend
AQ
02/13ALLERGAN : Declares First Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share..
AQ
02/09ALLERGAN (NYSE : AGN) announces a quarterly dividend of  $0.72
AQ
More news
News from SeekingAlpha
08:56aAllergan partner Medicines360 files U.S. application for extended duration of.. 
08:47aAnother Phase III Win For Neurocrine Biosciences 
05:18aiShares Mortgage Real Estate ETF - Methodology Makes All The Difference 
02/21Tracking David Tepper's Appaloosa Management Portfolio - Q4 2017 Update 
02/20Neurocrine Biosciences Shows Again That Sometimes The Tortoise Wins 
Financials ($)
Sales 2018 15 195 M
EBIT 2018 7 274 M
Net income 2018 -1 302 M
Debt 2018 22 990 M
Yield 2018 1,83%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,00x
EV / Sales 2019 4,65x
Capitalization 52 984 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 217 $
Spread / Average Target 36%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Matthew M. Walsh Chief Financial Officer & Executive VP
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
James H. Bloem Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-1.83%52 984
JOHNSON & JOHNSON-6.33%349 006
NOVARTIS-2.67%224 221
PFIZER-0.58%213 155
ROCHE HOLDING LTD.-9.33%206 183
MERCK AND COMPANY-2.29%148 618